Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir with and without Maraviroc Coadministration
Rattachement africain : it, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Raltegravir and maraviroc represent new, important resources for HIV-infected patients with intolerance or resistance to other antiretroviral agents. The safety and efficacy of both drugs have been investigated, but there is no information on possible pharmacokinetic interactions between these 2 drugs in clinical practice. OBJECTIVE: To evaluate raltegravir plasma concentrations in heavily treatment-experienced patients receiving salvage regimens and explore, in a preliminary assessment, the potential influence of maraviroc coadministration and other cofactors on raltegravir trough concentrations (C(trough)). METHODS: Fifty-four HIV-infected patients with triple class (nucleoside reverse transcriptase inhibitor, nonnucleoside reverse transcriptase inhibitor, protease inhibitor) treatment experience starting raltegravir 400 mg twice daily, with (n = 11) or without (n = 43) concomitant maraviroc 300 mg twice daily, were evaluated. All regimens included at least 3 drugs of at least 2 different classes. Raltegravir plasma Ctrough, after at least 1 month of treatment, were analyzed to compare groups of patients taking raltegravir only and raltegravir plus maraviroc. Immunovirological (CD4, HIV-RNA) and clinical data after 6 months of treatment were also collected and described. RESULTS: Raltegravir plasma Ctrough showed a large variability (range <0.020-2.47 microg/mL). Median levels were similar in the 2 groups (raltegravir + maraviroc 0.104 microg/mL, range 0.025-0.826; raltegravir 0.090 microg/mL, range <0.020-2.47, p = 0.400). Detectable (>0.02 microg/mL) raltegravir concentrations were observed in all patients receiving raltegravir + maraviroc and in 74% of patients receiving raltegravir alone (p = 0.060). After 6 months of treatment, the 2 groups had similar clinical, virologic, and immunologic conditions. CONCLUSIONS: Coadministration of maraviroc does not seem to have any relevant effects on raltegravir plasma Ctrough in heavily treatment-experienced patients receiving salvage regimens. Further studies should evaluate the potential additional benefits of maraviroc coadministration in terms of virologic and immunologic response.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir with and without Maraviroc Coadministration
- Date Crossref
- 01/05/2010
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Istituto Superiore di Sanità pays non établi dans la noticeOrganisme public
-
Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la noticeÉtablissement de santé
-
University of Bari Aldo Moro Clinical Infectious Diseases Specialist pays non établi dans la noticeUniversité ou école supérieure
-
University of Perugia Clinic of Infectious Diseases pays non établi dans la noticeUniversité ou école supérieure
-
Sapienza University of Rome pays non établi dans la noticeUniversité ou école supérieure
-
Ospedale di Belcolle pays non établi dans la noticeÉtablissement de santé
-
Foundation Center pays non établi dans la noticeOrganisation à but non lucratif
-
Silvia Baroncelli BSc pays non établi dans la noticeInstitution
-
Clinical Pharmacokinetics Unit Researcher pays non établi dans la noticeÉtablissement de santé
-
Liliana E Weimer MD pays non établi dans la noticeInstitution
-
Clinical Infectious Diseases Specialist Chiara Tommasi MD pays non établi dans la noticeÉtablissement de santé
-
La Sapienza University Department of Tropical and Infectious Diseases pays non établi dans la noticeUniversité ou école supérieure
Istituto Superiore di Sanità, Istituti di Ricovero e Cura a Carattere Scientifico et Clinical Infectious Diseases Specialist — University of Bari Aldo Moro, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.